Repare Therapeutics Inc (RPTX)
Official siteBIOTECHNOLOGY
Last updated: Jan 28, 2026 at 4:00 PM ET
Repare Therapeutics Inc (RPTX) Financials: Revenue, Profit and Cash Flow
Repare Therapeutics reported revenue of $53.48M for the fiscal year ended Dec 31, 2024, up 4.6% from the year before. That year, net income was -$84.69M with a net margin of -158.4%, operating cash flow was -$76.44M and free cash flow was -$76.44M. The quarter ended Sep 30, 2025 had revenue of $11.62M and net income of $3.26M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $53.48M | +4.6% | 100.0% | -174.9% | -158.4% |
| Dec 2023 | $51.13M | -61.2% | 100.0% | -227.3% | -183.4% |
| Dec 2022 | $131.83M | +1634.6% | 100.0% | -15.0% | -22.0% |
| Dec 2021 | $7.60M | +5529.6% | 100.0% | -1429.7% | -1406.7% |
| Dec 2020 | $135.00K | N/A | 100.0% | -40223.7% | -39568.1% |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $53.48M | $51.13M | $131.83M | $7.60M | $135.00K | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $407.00K | $102.00K |
| Gross profit | $53.48M | $51.13M | $131.83M | $7.60M | $135.00K | $0 | -$407.00K | -$102.00K |
| Research and development | $115.94M | $133.59M | $119.07M | $90.05M | $40.09M | $21.00M | $9.91M | $4.40M |
| Operating income | -$93.52M | -$116.22M | -$19.80M | -$108.66M | -$54.30M | -$26.38M | -$12.82M | -$6.17M |
| Net income | -$84.69M | -$93.80M | -$29.05M | -$106.91M | -$53.42M | -$27.22M | -$14.28M | -$7.80M |
| EBITDA | N/A | N/A | -$19.79M | -$107.26M | -$54.09M | N/A | N/A | N/A |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.62M | $250.00K | $0 | -$53.48M | $0 | $1.07M | $52.40M | $13.05M | $2.16M | $30.25M | $5.68M | $18.20M |
| Gross profit | $11.62M | $250.00K | $0 | -$454.00K | $0 | $1.07M | $52.40M | $13.05M | $2.16M | $30.25M | $5.68M | $18.20M |
| Operating income | $1.13M | -$17.78M | -$31.19M | -$30.65M | -$36.37M | -$37.32M | $10.82M | -$30.87M | -$38.42M | -$12.26M | -$34.68M | -$19.63M |
| Net income | $3.26M | -$16.74M | -$30.04M | -$28.67M | -$34.41M | -$34.77M | $13.16M | -$28.03M | -$18.88M | -$11.95M | -$34.94M | -$31.66M |
Balance Sheet
As of Dec 2024, cash and equivalents exceeded short-term debt of $1.84M by $82.87M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $176.51M | $253.90M | $364.07M | $368.71M | $357.09M | $102.69M | $13.93M | N/A |
| Current assets | $171.15M | $243.69M | $353.98M | $351.41M | $346.55M | $98.57M | $12.05M | N/A |
| Cash and equivalents | $84.72M | $111.27M | $159.52M | $334.43M | $326.18M | $94.80M | $10.73M | N/A |
| Total liabilities | $25.38M | $41.82M | $84.56M | $80.29M | $70.26M | $12.83M | $36.31M | N/A |
| Short-term debt | $1.84M | $2.40M | $2.17M | $1.72M | $697.00K | $625.00K | N/A | N/A |
| Shareholder equity | $151.13M | $212.08M | $279.52M | $288.42M | $286.83M | -$46.13M | -$22.38M | N/A |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $126.75M | $130.49M | $144.02M | $176.51M | $206.39M | $235.34M | $263.08M | $253.90M | $286.41M | $301.59M | $336.31M | $364.07M |
| Total liabilities | $11.62M | $20.09M | $18.93M | $25.38M | $31.43M | $31.67M | $31.13M | $41.82M | $53.04M | $56.17M | $85.06M | $84.56M |
| Cash and equivalents | $72.83M | $67.66M | $84.45M | $84.72M | $80.54M | $79.82M | $103.22M | $111.27M | $107.37M | $115.54M | $121.46M | $159.52M |
| Shareholder equity | $115.13M | $110.41M | $125.10M | $151.13M | $174.96M | $203.68M | $231.95M | $212.08M | $233.37M | $245.41M | $251.24M | $279.52M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$76.44M | -$127.16M | $322.00K | -$85.80M | -$6.08M | -$18.43M | -$12.62M | -$6.01M |
| Capital expenditures | $0 | $1.94M | $602.00K | $1.69M | $2.24M | $1.30M | $583.00K | $1.16M |
| Free cash flow | -$76.44M | -$129.10M | -$280.00K | -$87.49M | -$8.32M | -$19.73M | -$13.20M | -$7.16M |
| Investing cash flow | $49.47M | $78.04M | -$175.78M | -$1.68M | -$9.76M | -$1.30M | -$583.00K | -$1.16M |
| Financing cash flow | $542.00K | $842.00K | $880.00K | $95.56M | $247.84M | $103.24M | $103.24M | $30.46M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.65M | -$16.34M | -$29.13M | -$27.32M | -$30.54M | -$30.51M | $11.93M | -$28.16M | -$32.87M | -$34.35M | -$31.79M | -$29.64M |
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $398.00K | $0 | $1.06M | $475.00K | $1.72M |
| Free cash flow | $2.65M | -$16.34M | -$29.13M | -$27.32M | -$30.54M | -$30.51M | $11.93M | -$28.55M | -$32.87M | -$35.41M | -$32.26M | -$31.36M |
Frequently Asked Questions About RPTX
What is Repare Therapeutics' annual revenue?
Repare Therapeutics reported revenue of $53.48M for the fiscal year ended Dec 31, 2024.
How fast is Repare Therapeutics' revenue growing?
Revenue was up 4.6% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was 91.6%.
Is Repare Therapeutics profitable?
No. Repare Therapeutics reported net income of -$84.69M for the fiscal year ended Dec 31, 2024, with a net margin of -158.4%.
How much free cash flow does RPTX generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of -$76.44M minus capital expenditures of $0 produced free cash flow of -$76.44M.
How much debt does Repare Therapeutics have?
The balance sheet dated Dec 31, 2024 reported short-term debt of $1.84M and cash and equivalents of $84.72M.
RPTX pages: Overview, Financials